Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by brad129on Jan 23, 2022 7:43pm
161 Views
Post# 34350610

RE:RE:RE:Aristotle testing volumes and daily schedule

RE:RE:RE:Aristotle testing volumes and daily schedule

Sounds great on paper, sure hope your assumptions come to fruition, I still think back to Bully's charts posting testing numbers. I sure hope they aren't trying to hire a lawyer for 150-200k a year and then hitting more private placements to cover their wage.



LithLover wrote:

Nope. I think 2/3 of people booking a consult is reasonable to follow through with a test.  But let's say only 1/3 book and it's only 5 tests per day thats 30 a week.  $3 million a year from Aristotle.  $4 million from Care.  $7 million and say the industry valuation is on the low end of the 10-14 times revenue   Still $70 million valuation 

Doesn't account for covid or any other revenues and still values us at $0.80/share.  $0.80 on the low side $1.60 on the high   

I don't expect these numbers to show in Q4 for March 31 but Q1 2022 for mid May should be reflected.  

 

 
 

brad129 wrote: That's a lot of assumptions, don't you think?

 

 



<< Previous
Bullboard Posts
Next >>